Innovative Steps by PainReform in the Cataract Surgery Field
PainReform Ltd. (Nasdaq: PRFX) is making significant strides in the surgical arena by completing a strategic investment in LayerBio, Inc. This Boston-based biotechnology company specializes in advanced drug delivery technologies specifically aimed at ophthalmic applications. The synergy between these two companies aims to tackle the growing demand in the global cataract surgery market, a sector that is projected to reach substantial financial heights.
Meeting the Needs of Patients and Surgeons
With an ever-increasing number of cataract surgeries being performed, the market presents a unique opportunity for innovation. Currently, the U.S. reports a startling 4.5 million cataract surgeries performed each year, driven by an aging population and advancements in medical technology. Traditional postoperative care usually involves a complex regimen of eye drops, including both corticosteroids and NSAIDs, which often leads to compliance issues, especially among the elderly. PainReform and LayerBio are poised to introduce a more efficient alternative through their collaboration.
Introducing OcuRing™-K: A Game Changer
LayerBio’s flagship product, OcuRing™-K, represents a major leap forward in pain management after cataract surgeries. This intraocular ring allows for the localized, sustained release of Ketorolac, an effective non-steroidal anti-inflammatory drug. The OcuRing™-K not only simplifies the postoperative process by removing the need for daily eye drops but also reduces potential side effects associated with traditional treatments.
Advantages of a Dropless Treatment
The innovative design of OcuRing™-K provides numerous advantages over the conventional treatment methods. Its single-application nature allows for continuous drug delivery directly to the surgical site, minimizing systemic exposure to the medication while maintaining effectiveness. This is especially beneficial for elderly patients or those with difficulty adhering to complex treatment regimens. In this regard, the OcuRing™-K meets a crucial need expressed by both patients and healthcare providers alike.
Future Directions for PainReform and LayerBio
The partnership between PainReform and LayerBio is paving the way for advancing OcuRing™-K through necessary stages for clinical testing in the U.S. Regulatory approval could unlock a reimbursable market filled with potential. Beyond cataract surgery, the companies are also considering the technology for broader applications in areas such as glaucoma treatment and anti-infection therapies.
Leadership and Development at LayerBio
Under the guidance of Dr. Ken Mandell, LayerBio is well-positioned for future growth. Dr. Mandell’s wealth of experience and expertise in sustained-release drug delivery will facilitate LayerBio’s operational and development strategies. His past achievements and ongoing role will ensure that the company remains at the forefront of innovation within the ophthalmic sector.
About PainReform Ltd.
PainReform Ltd. is dedicated to advancing healthcare through the reformulation of established therapeutics. Additionally, it drives innovation with its AI-driven energy optimization technologies. Their commitment to pioneering solutions in healthcare aligns perfectly with their mission to enhance patient care through efficiency and effectiveness. PainReform’s dual focus on healthcare and energy solutions showcases its versatility in addressing the challenges of modern therapeutics and sustainable energy needs.
Contact Information
For any inquiries, you can reach Crescendo Communications, LLC at 212-671-1021. For direct communication with PainReform, reach out to Dr. Ehud Geller, Chairman and interim CEO, at +972-54-4236711.
Frequently Asked Questions
What is PainReform's recent investment about?
PainReform has completed a strategic investment in LayerBio to enhance postoperative care in cataract surgery.
What is OcuRing™-K?
OcuRing™-K is a novel intraocular ring designed to deliver an anti-inflammatory drug effectively during and after cataract surgeries.
How does OcuRing™-K improve patient care?
This device eliminates the need for daily eye drops, ensuring consistent drug delivery directly to the surgical site and enhancing patient compliance.
What are the future plans for PainReform and LayerBio?
They plan to advance OcuRing™-K through further clinical development and explore its applications in other ophthalmic procedures.
Who is leading LayerBio?
Dr. Ken Mandell, a recognized leader in drug delivery systems, is the CEO guiding LayerBio's product development efforts.
